Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Quanterix ( (QTRX) ) has provided an update.
Quanterix announced on May 12, 2026, that Chief Financial Officer and Treasurer Vandana Sriram will depart the company, with her tenure ending effective June 15, 2026, under a planned transition. The company emphasized that her exit is not related to any disagreements over accounting, financial statements, internal controls, or operations, and that she will receive severance benefits consistent with her employment agreement.
Management highlighted Sriram’s contributions since joining in 2023, citing her role in strengthening cost discipline, cash management, and the company’s path toward cash flow breakeven and synergy targets. Quanterix has engaged a leading executive search firm to find her successor, aiming to ensure continuity in financial leadership as it pursues its strategy in biomarker detection and integrated precision medicine.
The most recent analyst rating on (QTRX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.
Spark’s Take on QTRX Stock
According to Spark, TipRanks’ AI Analyst, QTRX is a Neutral.
QTRX scores low primarily due to heavy ongoing losses and persistent negative free cash flow, despite a relatively low-debt balance sheet. Technicals also weigh on the score given a pronounced downtrend and negative momentum. The earnings call adds some support via reiterated guidance, >50% non-GAAP gross margins, and a path to H2 2026 cash-flow breakeven, but organic revenue declines and weaker pharma demand remain key risks.
To see Spark’s full report on QTRX stock, click here.
More about Quanterix
Quanterix is a global leader in ultra-sensitive biomarker detection, providing its proprietary Simoa technology to enable breakthroughs in disease research, diagnostics, and drug development. The company expanded its portfolio in 2025 by acquiring Akoya Biosciences, adding multiplexed tissue imaging with single-cell resolution and building an integrated platform that links blood and tissue biology for precision medicine.
Quanterix supports the scientific community with a large body of peer-reviewed research and a substantial installed instrument base, positioning itself as a key player in biomarker-driven precision medicine. Its combined capabilities across liquid biopsy and spatial biology aim to advance applications from discovery to diagnostics, reinforcing its role in healthcare innovation and translational research.
Average Trading Volume: 958,653
Technical Sentiment Signal: Sell
Current Market Cap: $133.1M
Learn more about QTRX stock on TipRanks’ Stock Analysis page.